Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future

Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice

(2014) D. Cathelin et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children

(2014) Aditi Sinha et al.   KIDNEY INTERNATIONAL

A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease

(2014) Takehiko Wada et al.   KIDNEY INTERNATIONAL

Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease

(2014) Rutger J.H. Maas et al.   KIDNEY INTERNATIONAL

Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?

(2014) Detlef Schlöndorff   KIDNEY INTERNATIONAL

The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis

(2014) Björn Meijers et al.   KIDNEY INTERNATIONAL

The search goes on: suPAR is not the elusive FSGS factor

(2014) Jeroen K. Deegens et al.   Nature Reviews Nephrology

Management of Severe Recurrent Focal Segmental Glomerulosclerosis Through Circulating Soluble Urokinase Receptor Modification

(2013) Christian Morath et al.   AMERICAN JOURNAL OF THERAPEUTICS

Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis

(2013) S. Beaudreuil et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Serum suPAR in patients with FSGS: trash or treasure?

(2013) Rutger J. H. Maas et al.   PEDIATRIC NEPHROLOGY

Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates

(2013) Carlos R. Franco Palacios et al.   TRANSPLANTATION

Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1

(2012) Jessica J Harris et al.   JOURNAL OF PATHOLOGY

Circulating suPAR in Two Cohorts of Primary FSGS

(2012) C. Wei et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Serum-soluble urokinase receptor concentration in primary FSGS

(2012) Rutger J.H. Maas et al.   KIDNEY INTERNATIONAL

Resolution of Recurrent Focal Segmental Glomerulosclerosis after Retransplantation

(2012) Lorenzo Gallon et al.   NEW ENGLAND JOURNAL OF MEDICINE

TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation

(2012) Martin Bitzan et al.   PEDIATRIC NEPHROLOGY

New Insights Into Human Minimal Change Disease: Lessons From Animal Models

(2011) Sumant S. Chugh et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

(2011) Changli Wei et al.   NATURE MEDICINE

Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome

(2010) J.-M. J. HESLAN et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?

(2009) Alain Y. Meyrier   KIDNEY INTERNATIONAL

Hemopexin Induces Nephrin-Dependent Reorganization of the Actin Cytoskeleton in Podocytes

(2008) R. Lennon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity

(2008) Virginia J. Savin et al.   Translational Research